Navigation Links
Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkin's Lymphoma
Date:10/15/2008

Zevalin(R) First-Line Indolent (FIT) Phase III Clinical Trial results

published in Journal of Clinical Oncology

SEATTLE, Oct. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Journal of Clinical Oncology has published the results of the First-line Indolent Trial (FIT) demonstrating that use of Zevalin(R)([90Y]-ibritumomab tiuxetan) in consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma provided important patient benefits including a significant improvement in progression free survival. A companion editorial discussed the growing evidence for the efficacy of radioimmunotherapy (RIT) in B-cell lymphomas. Cell Therapeutics has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for use of Zevalin in first-line consolidation therapy based on the FIT data.

Oliver W. Press, M.D., Ph.D., Member of the Fred Hutchinson Cancer Research Center and Professor at the University of Washington, commented in his editorial that the studies "confirm and extend prior data demonstrating the tremendous potential of RIT in the treatment of B-cell NHL at diagnosis and after relapse at both conventional and myeloablative doses. Despite the overwhelming body of evidence, however, RIT remains underused in the United States and other countries. The reasons for this underuse have been widely debated but seem to be related, at least partially, to logistic issues involved in the transfer of care from the hematologist/oncologist to the nuclear medicine physician, concerns about inadequate reimbursement by Medicare for RIT, and exaggerated emphasis on delayed effects such as marrow damage and secondary malignancies. It is hoped that studies such as those in this issue would encourage wider appreciation and use of RIT."

"We couldn't agree more with Dr. Press' comments about
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing
2. Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years
3. Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT
4. Landmark HIV/AIDS Publication Launches at International AIDS Society Conference in Mexico City
5. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
6. TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
7. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
8. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
9. Hospital Launches Landmark Emergency Medicine Project
10. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
11. Viatronix V3D-Colon Utilized in Another Landmark Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... WELWYN GARDEN CITY, England and ... Heptares Therapeutics, the leading GPCR drug discovery and development company, ... Akira Usui as a Consultant to augment the Company,s ... Asian territories. Mr Usui has more than 15 years ... pharmaceutical industry including senior roles at Perlegen Sciences, Inc., Roche Pharma ...
(Date:5/23/2013)... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Executive Officer of Neurocrine Biosciences, will be presenting at the ... in Boston.   The live presentation takes place ... 8:20 a.m. Pacific Time.  The presentation will be webcast and ... . If you are unable to attend ...
(Date:5/23/2013)... Hearing health affects a man,s lifestyle, and if ... and professionally engaged, he should address any hearing loss he ... Better Hearing Institute (BHI) is delivering to men ... Week , which leads up to and includes Father,s Day. ... through June 16. To help men address ...
Breaking Medicine Technology:Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4
... YORK, Nov. 14, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0203105/The-Outlook-for-Pharmaceuticals-in-Northern-Europe.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory ... to represent a combined pharmaceutical market value ...
... MALVERN, Pa., Nov. 13, 2011 TetraLogic ... mimetic drugs to treat cancer, today announced presentations of ... TL32711 at the 2011 AACR-NCI-EORTC International Conference: Molecular ... nearing completion of a single agent Phase 1 study ...
Cached Medicine Technology:The Outlook for Pharmaceuticals in Northern Europe 2The Outlook for Pharmaceuticals in Northern Europe 3The Outlook for Pharmaceuticals in Northern Europe 4TetraLogic Pharmaceuticals Announces Presentation of Data on Smac Mimetic TL32711 at AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 2
(Date:5/24/2013)... Chronic Fatigue Syndrome has been a mysterious ... fatigue lasting 6 months or longer. Symptoms of Chronic ... impairment, muscle and joint pain without swelling or redness, ... malaise that lasts for more than 24 hours. ... linked to insulin resistance. At a healthy body weight, ...
(Date:5/24/2013)... Concern have today released updated guidelines on Hormone Replacement ... HRT, the benefits and the risks. The new guidelines ... , published by SAGE. , Over the last ... "elixir of youth" to being considered extremely risky and ... publication of the Women,s Health Initiative (WHI) trial in ...
(Date:5/24/2013)... Wednesday, 15th May 2013 | 10am BST ... access webinar playback: http://bit.ly/10Rt0ZH , Ongoing regulatory changes ... Across the globe and particularly in Europe, a number of ... activity . For dealmakers, understanding how the likes of Basel ... affects your corner of the market will give you a ...
(Date:5/24/2013)... 2013 HCG EZ Drops has been ... to announce it’s new weight loss initiative. “We are so confident ... our customers their money back if they don’t lose 21 pounds ... EZ Drops. “The HCG Diet consists of 21 days of ... in 21 days.” , The controversial, cutting-edge diet has been hailed ...
(Date:5/24/2013)... UK (PRWEB) May 24, 2013 The leading ... 50% discount offer on short prom dresses . Now ... quality that is standard with the brand name since its ... collections in prom dresses. And now this huge discount offer ... , “I feel highly privileged to announce that ...
Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New hCG Diet Plans to Promote Fast Weight Loss Shown to Reduce the Risk & Symptoms of Chronic Fatigue 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New hCG Diet Plans to Promote Fast Weight Loss Shown to Reduce the Risk & Symptoms of Chronic Fatigue 3Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 2Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 3Health News:short prom dresses Offers Abnormally Low Discount on Its New Collections 2
... readmitted within a year, study finds , , WEDNESDAY, April ... discharged from the hospital is readmitted within 30 days, ... a year, a new study finds. , The groundbreaking ... that researchers believe could be prevented through better care ...
... Calif., April 1, 2009 UC Irvine pharmacological researchers ... regulation can limit cocaine cravings. Their findings could herald ... Shinjae Chung and Olivier Civelli, the study identified how ... "pleasure center" to create an addictive response to cocaine ...
... NVAX) announced today that it has ... common stock at $0.88 per share to a wholly owned subsidiary ... Novavax and Cadila. Novavax intends to use the $11 million in ... 4.75% senior convertible notes due in July 2009 and for a ...
... April 1 Medicare beneficiaries who need physical ... efficient to obtain treatment under legislation introduced yesterday ... Patient Access to Physical Therapists Act (HR 1829), ... (R-PA), and Tammy Baldwin (D-WI), eliminates the need ...
... AILA believes this reform must include a rational model for giving American ... that can open the door to innovation and international markets. , ... ... fuel to speed it to recovery. And, once recovered, it ...
... April 1 On April 1st, Professional Healthcare Resources ... patients in their homes. The company was started in ... and has grown to an organization offering home health, ... of Columbia, and Virginia. The company has over 700 ...
Cached Medicine News:Health News:High Rate of Rehospitalizations Costing Billions 2Health News:High Rate of Rehospitalizations Costing Billions 3Health News:UCI researchers find new way to fight cocaine addiction 2Health News:Novavax Announces Closing of $11 Million Common Stock Sale to Subsidiary of Cadila Pharmaceuticals 2Health News:Legislation Aims to Increase Access to Physical Therapist Services By Eliminating Physician Referral Requirement 2Health News:Legislation Aims to Increase Access to Physical Therapist Services By Eliminating Physician Referral Requirement 3Health News:AILA Believes There Has To Be a Better Way When It Comes to the H-1B Lottery 2Health News:AILA Believes There Has To Be a Better Way When It Comes to the H-1B Lottery 3Health News:Professional Healthcare Resources Celebrates 15 Year Anniversary 2
... is the first truely web-based solution on the ... POC (managed from the lab) and Critical Care ... of AegisPOC ensures that all groups have the ... in the manner best suited to them. Through ...
...
... The Vari-Lase Endovenous Laser System is ... for varicose veins in the leg. Endovenous ... surgical vein-stripping for the treatment of varicose ... laser fiber is inserted into the varicosed ...
Using proven 1064 nm technology for the treatment of deeper lesions, the Lumenis One Multi-Spot Nd:YAG module provides versatility allowing targeted treatment of leg veins, vascular lesions, facial w...
Medicine Products: